DRAMATIC EFFICACY OF LOWEST INHALATIONAL LIDOCAINE DOSES FOR THE REFRACTORY COUGH; RETROSPECTIVE-OBSERVATIONAL STUDY
Main Article Content
Abstract
Objectives: to evaluate this hypothesis might include: What is lidocaine? What is the refractory cough? How can nebulised lidocaine make the improvement of refractory cough? Is the study supported by past publicized literature studies? Is there a relationship between them and the improvement refractory cough? What is the magnitude of both refractory cough response and lidocaine adverse effects in the study?
Method: My study was an observational retrospective for 62 cases. The study was conducted in a physician outpatient clinic. The aut hor reported the 62 cases of refractory cough over nearly 12-months, started from March 10, 2019, and ended on March 10, 2020. Only two different doses within the normal range of lidocaine 2% solution using inhaled nebulizer were used. Both adverse effects (safety) and anti –tussive responses (efficacy) were recorded. Suggesting hypothesis: Nebulised lidocaine can improve the refractory cough.
Results: Range of age in group I was 16-80 years and in group II was 16-84 years, but with an insignificant P-value (0.730). There is a slight female sex Predominance for both groups (51.61%). The dramatic response for the group I was: (75.86%) and the weak response for the grou p I (24.14%). The dramatic response for group II was: (93.94%), and the weak response for group II was: (6.06%).
Conclusions: The author concluded that the efficacy of inhalational lowest lidocaine doses for the refractory cough with minimum adverse drug reactions. Very few and mild side effects encourage the generalizing use of lidocaine in the refractory cough and cough.
Downloads
Article Details
References
Alexander S. Discovery and development of major drugs currently in use. In Ralph Landau, Basil Achilladelis & Alexander Scriabine (eds.). Pharmaceutical Innovation: Revolutionizing Human Health. Philadelphia: Chemical Heritage Press. 1999; p. 211. ISBN 9780941901215. Archived from the original on 2017-09-08.
Wildsmith JAW. Lidocaine: A more complex story than 'simple' chemistry suggests. The Proceedings of the History of Anaesthesia Society. 2011;43: 9–16. (Accessed on: April 22, 2014)
Löfgren N. Studies on local anesthetics: Xylocaine: a new synthetic drug (Inaugural dissertation). Stockholm, Sweden: Ivar Heggstroms. 1948;OCLC 646046738.
Weinberg L, Peake B, Tan C, Nikfarjam M. Pharmacokinetics and pharmacodynamics of lignocaine: A review. World J Anesthesiol. 2015; 4(2): 17-29. DOI: https://dx.doi.org/10.5313/wja.v4.i2.17
Middleton RM, Shah A, Kirkpatrick MB. Topical nasal anesthesia for flexible bronchoscopy: a comparison of four methods in normal subjects and in patients undergoing transnasal bronchoscopy. Chest. 1991; 99:1093–6. PMID:2019163 DOI:10.1378/chest.99.5.1093
Hansson L, Midgren B, Karlsson JA. Effects of inhaled lignocaine and adrenaline on capsaicin-induced cough in humans. Thorax. 1994; 49:1166–8. DOI: 10.1136/thx.49.11.1166 PMID: 7831637 PMCID: PMC475284
Groeben H, Silvanus MT, Beste M et al. Both intravenous and inhaled lidocaine attenuate reflex bronchoconstriction but at different plasma concentrations. Am J Respir Crit Care Med. 1999; 159:530–5. DOI:10.1164/ajrccm.159.2.9806102 PMID:9927369
Hunt LW, Frigas E, Butterfield JH et al. Treatment of asthma with nebulized lidocaine: a randomized, placebo controlled study. J Allergy Clin Immunol. 2004; 113:853–9. PMID:15131566 DOI:10.1016/j.jaci.2004.02.039
Xylocaine and xylocaine with adrenaline: Product information. AstraZeneca Pty Ltd A, 2010. PAIN.000-118-391.6.0 Date of most recent amendment: 20 September 2010.
Cassuto J, Sinclair R, Bonderovic M. Anti-inflammatory properties of local anesthetics and their present and potential clinical
implications. Acta Anaesthesiol Scand. 2006; 50: 265-282. PMID:16480459 DOI: 10.1111/j.1399-6576.2006.00936
Hollmann MW, Durieux ME. Local anesthetics and the inflammatory response: a new therapeutic indication? Anesthesiology. 2000; 93: 858-875. PMID: 10969322 DOI: 10.1097/00000542-200009000-00038
Sinclair R, Eriksson A, Gretzer C, Cassuto J, Thomsen P. Inhibitory effects of amide local anaesthetics on stimulus-induced human leukocyte metabolic activation, LTB4 release and IL-1 secretion in vitro. Acta Anaesthesiol Scand. 1993; 37: 159-65. PMID: 8383401 DOI: 10.1111/j.1399-6576.1993.tb03693.x
Rimbäck G, Cassuto J, Wallin G, Westlander G. Inhibition of peritonitis by amide local anesthetics. Anesthesiology. 1988; 69: 881-886. PMID: 3195759 DOI: 10.1097/00000542-198812000-00013
Serhan CN. Eicosanoids in leukocyte function. Curr Opin Hematol 1994; 1: 69-77. PMID: 9371262
Hendrickson HS, van Dam-Mieras MC. Local anesthetic inhibition of pancreatic phospholipase A2 action on lecithin monolayers. J Res. 1976; 17: 399-405. PMID: 133195
Kunze H, Bohn E, Vogt W. Effects of local anaesthetics on prostaglandin biosynthesis in vitro. Biochim Biophys Acta. 1974; 360: 260-269. PMID: 4278080 DOI: 10.1016/0005-2760(74)90055-1
Goel RK, Tavares IA, Nellgard P, Jonsson A, Cassuto J, Bennett A. Effect of lignocaine on eicosanoid synthesis by pieces of human gastric mucosa. J Pharm Pharmacol. 1994; 46: 319-320. PMID: 8051618 DOI: 10.1111/j.2042-7158.1994.tb03803.x
Goldstein IM, Lind S, Hoffstein S, Weissmann G. Influence of local anesthetics upon human polymorphonuclear leukocyte function in vitro. Reduction of lysosomal enzyme release and superoxide anion production. J Exp Med. 1977; 146: 483-494. PMID: 195003 DOI: 10.1084/jem.146.2.483
Mikawa K, Akamarsu H, Nishina K, Shiga M, Obara H, Niwa Y. Effects of ropivacaine on human neutrophil function: comparison with bupivacaine and lidocaine. Eur J Anaesthesio.l 2003; 20: 104-110. PMID: 12622492 DOI: 10.1017/S026502150300019X
Chan DS, Wang HH. Local anesthetics can interact electrostatically with membrane proteins. Biochim Biophys Acta 1984; 770: 55-64. PMID: 6320881 DOI: 10.1016/0005-2736(84)90073-7
Olschewski A, Hempelmann G, Vogel W, Safronov BV. Blockade of Na+ and K+ currents by local anesthetics in the dorsal horn neurons of the spinal cord. Anesthesiology 1998; 88: 172-179 PMID: 9447870 DOI:10.1097/00000542-199801000-00025
Feldman JM, Chapin-Robertson K, Turner J. Do agents used for epidural analgesia have antimicrobial properties? Reg Anesth. 1994; 19: 43-47. PMID: 8148293 DOI: 10.1097/00000542-199109001-00834.
Wu FL, Razzaghi A, Souney PF. Seizure after lidocaine for bronchoscopy: case report and review of the use of lidocaine in airway anesthesia. Pharmacotherapy. 1993; 13:72–8. PMID:8437971
Langmack EL, Martin RJ, Pak J et al. Serum lidocaine concentrations in asthmatics undergoing research bronchoscopy. Chest. 2000 Apr; 117:1055–60. PMID:10767239 DOI:10.1378/chest.117.4.1055
Biller JA. Airway obstruction, bronchospasm, and cough. In Berger AM, Shuster JL, Von Roenn JH (eds.). Principles and practice of palliative care and supportive oncology. Inhaled lidocaine is used to suppress cough during bronchoscopy. Animal studies and a few human studies suggest that lidocaine has an antitussive effect. Hagerstwon, MD: Lippincott Williams & Wilkins. 2007. pp. 297–307. ISBN 978-0-7817-9595-1.
Trochtenberg s. Nebulized Lidocaine in the Treatment of Refractory Cough. Chest. 1994 May; 105(5):1592-1593. Available online: https://doi.org/10.1378/chest.105.5.1592
Monograph Lidocaine. American Hospital Formulary Services. Available from: www.medicinescomplete.com. Accessed on the 03/04/2017.
Monograph Antitussives. Palliative Care Formulary. Available from: www.palliativedrugs.com. Accessed on the 03/04/2017.
Udezue E. Lidocaine inhalation for cough suppression. The American Journal of Emergency Medicine. 2001 May; 19 (3) 206-7.
Lingerfelt BM, Swainey CW, Smith TJ and Coyne PJ. Nebulized lidocaine for intractable cough near the end of life. The Journal of Supportive Oncology. 2007 Jul-Aug; 5 (7) :301-2.
Jackson D, Chen AH, Bennett CR. Identifying true lidocaine allergy. J Am Dent Assoc. 1994 Oct;125 (10): 1362–6. DOI:10.14219/jada.archive.1994.0180. PMID 7844301.
Australian Medicines Handbook. Adelaide, S. Aust: Australian Medicines Handbook Pty Ltd. 2006. ISBN 978-0-9757919-2-9.
BNF. Lidocaine hydrochloride (Lignocaine hydrochloride)British National Formulary (BNF 78) BMJ Group. Sep 2019-March 2020; 78:103. bnf.org. SBN:978 0 85711 352 8.
Irwin RS, French CL, Chang AB, et al. Classification of cough as a symptom in adults and management algorithms: CHEST Guideline and Expert Panel Report. Chest. 2018;153(1):196-209. PMID:29080708 PMCID:PMC6689094 DOI:10.1016/j.chest.2017.10.016
Shirk MB, Donahue KR, Shirvani J. Unlabeled Uses of Nebulized Medications. Am J Health Syst Pharm. 2006;63(18):1704-1716. PMID:16960254 DOI:10.2146/ajhp060015
Foster WM, Hurewitz AN. Aerosolized lidocaine reduces dose of topical anesthetic for bronchoscopy. Am Rev Respir Dis. 1992; 146:520–2. PMID:1489150 DOI:10.1164/ajrccm/146.2.520
Stolz D, Chhajed PN, Leuppi J et al. Nebulized lidocaine for flexible bronchoscopy: a randomized, double blind, placebo-controlled trial. Chest. 2005 Sep; 128:1756–60. PMID:16162784 DOI:10.1378/chest.128.3.1756